Bleepa TB Screening Pilot Now Live in Odisha

RNS Number : 6695G

Feedback PLC

31 March 2022

 

Feedback plc

Bleepa TB Screening Pilot Now Live in Odisha

· The 1^st patient has gone through Bleepa's cloud-based TB screening pathway at the Evangelical Hospital Khariar, India.

· The live pilot enables real-world illustration of Bleepa's capabilities and will strengthen further commercial and partnership discussions in India.

London, 31 March 2022 : Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, announces that its cloud TB screening service is now live at the Evangelical Hospital Khariar in Odisha, India. 

The service sees digital X-rays securely transmitted via mobile networks to the cloud where the images are analysed by Feedback's partner Qure.ai, before being shared with clinicians. Using Bleepa's pioneering capabilities a screening result can be available within minutes of an X-ray being acquired, almost anywhere in India.

The impact of this technology means that TB screening can now be expanded to rural areas where digital imaging was difficult to deliver. This enables current TB screening services to reach more people and grow the number of their existing screening contracts.

The pilot, run in partnership with Qure.ai and Amazon Web Services will now move into an evaluative stage where the system benefits will be measured as patients come through. In parallel the Company will pursue a number of opportunities to commercialise the system, leveraging the evidence generated by the pilot.

Annual India Radiological & Imaging Association Conference  

Feedback was delighted to attend the 74th Annual India Radiological & Imaging Association conference (IRIA 2022), bringing together thousands of India's top radiologists and specialists earlier this month. Feedback's Chief Marketing and Sales Officer Nick Mayhew joined a panel discussion on Global Radiology Innovations while the Company debuted Bleepa, BleepaBox and CareLocker.

Dr Tom Oakley, CEO of Feedback, said: "This is a great milestone for the Company, opening the gateway to a significant market and the opportunity to transform care for a great many people.

"India has made massive strides in the development and adoption of medical technology to support the diagnosis and treatment of diseases. We support India's vision to eliminate TB by 2025, five years ahead of the UN's SDG goals, and believe that we can make a significant contribution to help India reach this goal.  We are confident that our pilot programme will demonstrate the value of Bleepa to rapidly screen for TB, particularly in remote, resource-scarce locations where this has been a challenge."

Further information on Feedback and its products can be found on the Company's website: https://fbkmed.com/feedback-plc/reports-and-presentations/

-Ends-

Enquiries:

Feedback plc Tom Oakley, CEO Anesh Patel, CFO	[phone] [e-mail]
Panmure Gordon (UK) Limited (NOMAD and Broker) Emma Earl/Freddy Crossley (Corporate Finance) Rupert Dearden (Corporate Broking)	[phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus/Nick Rome/Nicholas Johnson	07980 541 893 or 07748 325 236 or 07884 664 686

About Feedback

Feedback plc is a specialist clinical communications business, with a mission to improve the efficiency and quality of communications for frontline clinicians and hospitals with a key focus on building solutions that enhance access to high quality patient data.

Feedback has developed a toolkit of clinical communications apps. Its core, regulatory approved product is Bleepa, a revolutionary medical imaging app enabling remote and secure communications between frontline clinicians and teams. CareLocker is an evolutionary GDPR compliant patient-centric cloud architecture - its proprietary technology enables an easy route to creation and mobilisation of individual healthcare records. Bleepa Box is a specialist tool to enable image transfer from remote settings to the Bleepa platform over mobile networks.

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based revenue model is expected to provide increasing levels of visibility as the Company grows its customer base.

 

END

 

 

MSCBRGDXUGXDGDG